VRNA - Verona Pharma Quarterly EPS earnings growth

Official company branding of Verona Pharma (VRNA)

David Zaccardi's team is currently adapting the business for the commercial implementation phase of its strategy. Verona Pharma plc (VRNA) relies on dual inhibition patents, offering a non-hormonal therapy method for COPD. Its status as a pulmonology innovator ensures physician confidence in its inhalation products. The quarterly EPS growth rate demonstrates financial resilience, where 115.20 represents the latest metric reading, confirming the issuer's fundamental strength.

Verona Pharma PLC (VRNA) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 10/18/2025

Analytical breakdowns for Verona Pharma plc

- share price and expert price forecast:
Summary company analytics:Verona Pharma plc
Flagship merchandise of Verona Pharma plc

Net income per share dynamics serve as a key indicator of capital allocation efficiency. This metric captures the percentage change in profit per quarter, allowing market noise to be filtered out from real business growth. An analysis of the quarterly EPS increase reveals the trend's resilience to corrections. For Verona Pharma plc (VRNA), this growth confirms the commercial success of its COPD treatments. High margins on new sales will ensure the company's transition to a stable cash flow.

Analysis of competing companies

HLN: Quarterly EPS earnings growth|Kenvue Corp - Year-over-year earnings per one share growth for the last 12 months|MENS (Jyong Biotech Limited) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months ligand.com LGND|Year-over-year earnings per share growth for the last twelve months Amneal (AMRX)|PRGO (Perrigo Company PLC) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ALVO (Alvotech S.A.)|Liquidia Technologies - Year-over-year earnings per share growth for the last twelve months|Galapagos Corp - Quarterly EPS earnings growth|ANIP (ANI Pharmaceuticals) - Year-over-year earnings per share growth for the last 12 months|MannKind Corp. (MNKD) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Corp) - Quarterly EPS earnings growth|SPRY: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth TBPH|Year-over-year net earnings per share change for the last twelve months Aquestive Therapeutics, Inc.|Year-over-year earnings per share growth for the last twelve months scPharmaceuticals Inc. SCPH|TECX: Year-over-year earnings per share growth for the last 12 months|TNXP - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months SXT Pharmaceuticals SXTC|EPRX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months bioharvest.com (BHST)|Year-over-year net earnings per share growth for the last 12 months EXOZ|ORMP: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Entera Bio Ltd. (ENTX)|HYFT (MindWalk Therapeutics) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ABVC (ABVC BioPharma, Inc)|Year-over-year earnings per one share growth for the last 12 months CPIX|QNTM - Year-over-year earnings per share growth for the last twelve months|FibroGen Corp (FGEN) - Year-over-year net earnings per share growth for the last 12 months|Telomir Pharmaceuticals Corp (TELO) - Year-over-year earnings per share growth for the last twelve months|Rani Therapeutics (RANI) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Synergy CHC Corp.|Earnings per share growth in annualized terms for the last twelve months rallybio.com RLYB|Quarterly EPS earnings growth LEXX|PULM: Year-over-year net earnings per share trend for the last twelve months|Pheton Holdings Ltd - Year-over-year net earnings per share growth for the last 12 months|APM - Year-over-year net earnings per share growth for the last 12 months|LYRA - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months IBO (Impact BioMedical)|TNF Pharmaceuticals Inc. (TNFA) - Year-over-year earnings per share growth for the last twelve months|cbdMD Corp - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months PRFX|Altamira Therapeutics (CYTO) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth LIPO|Quarterly EPS earnings growth optinose.com (OPTN)|Year-over-year earnings per share growth for the last twelve months Pieris Pharmaceuticals, Inc. PIRS|Procaps (PROC) - Earnings per share growth in annualized terms for the last twelve months|PTPI - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Qilian International Corp QLI|SLRN: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months TFFP (tffpharma.com)